AARTI DRUGS LTD.
AARTIDRUGS · General/Diversified · NSE
₹372
Current Market Price
Fair Value (DCF)
₹263
Margin of Safety
-29.2%
Updated 11h ago
YieldIQ Score
42/100
Piotroski F-Score
4/9
Economic Moat
Narrow
Confidence
12%
ROE
—
Debt/Equity
0.39
WACC
11.1%
Market Cap
₹3,395 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
14.3%
Return on capital employed
EV / EBITDA
13.2×
Enterprise multiple
Debt / EBITDA
2.1×
Leverage vs earnings
Interest Coverage
6.9×
EBIT covers interest
Current Ratio
1.60×
Short-term liquidity
Asset Turnover
0.92×
Revenue per ₹ of assets
Revenue CAGR (3Y)
-1.6%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹371.95
Bear case
₹146.85
MoS -153.3%
Base case
₹263.23
MoS -41.3%
Bull case
₹349.36
MoS -6.5%
Ratio Trends
AARTIDRUGS · last 9 annual periods
ROE
12.3%
ROCE
15.3%
Operating Margin
—
Debt / Equity
0.45×
PE
54.9×
EV / EBITDA
11.3×
Historical Financials
AARTIDRUGS · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹2155 Cr | ₹2489 Cr | ₹742 Cr | ₹620 Cr | ₹2369 Cr | +2.4% |
| EBITDA | — | ₹341 Cr | ₹308 Cr | ₹320 Cr | ₹303 Cr | -2.9% |
| EBIT | ₹392 Cr | ₹291 Cr | ₹81.9 Cr | ₹73.3 Cr | — | -34.2% |
| PAT | ₹280 Cr | ₹205 Cr | ₹56.2 Cr | ₹47.3 Cr | ₹168 Cr | -12.0% |
| EPS (diluted) | ₹30.09 | ₹22.12 | ₹6.07 | ₹5.15 | — | -35.7% |
| CFO | ₹155 Cr | ₹69.6 Cr | ₹134 Cr | ₹359 Cr | ₹245 Cr | +12.1% |
| CapEx | — | — | — | — | ₹-177 Cr | — |
| FCF | — | — | — | — | ₹67.4 Cr | +0.0% |
| Total Assets | — | ₹2208 Cr | ₹2421 Cr | ₹2432 Cr | ₹2575 Cr | +3.9% |
| Total Debt | — | — | ₹402 Cr | ₹287 Cr | ₹615 Cr | +11.2% |
| Shareholders' Equity | — | — | ₹1192 Cr | ₹1282 Cr | ₹1369 Cr | +3.5% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
AARTIDRUGS vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| RPGLIFE RPG LIFE SCIENCES LTD | -36.4% | 50 | Overvalued | 34.5% | — |
| GUJTHEM GUJTHEM | — | — | Pending | 19.6% | — |
| GUFICBIO GUFICBIO | — | — | Pending | 11.6% | — |
| ORCHPHARMA ORCHPHARMA | — | — | Pending | 7.9% | — |
| INNOVACAP INNOVACAP | — | — | Pending | 13.4% | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for AARTIDRUGS in the last 10 years.
AI Analysis Summary
Model-generated description of metrics. Not investment advice. AARTI DRUGS LTD. (AARTIDRUGS.NS) trades at 371.95 vs a model fair value of 263.23, a gap of -29.2%. Piotroski F-score: 4/9. Moat label: N...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of AARTIDRUGS →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for AARTIDRUGS →
Compare
Head-to-head with peers
Compare AARTIDRUGS side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse AARTIDRUGSNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.